Quoin Pharmaceuticals Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | $-1.90 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-1.77 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | $-1.74 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $-6.50 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | After market close | – | $-0.47 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | $-0.39 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | After market close | – | $-2.08 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | $-1.95 | – |
Press releases
Announcements Quoin Pharmaceuticals filed with the SEC
Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces FDA Grants Rare
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Private Placement Financing of Up
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Japan's MHLW
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update and Reports First
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Files Breakthrough Medicine
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Update and Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces U.S. FDA Grants
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization
Executive or director change · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update and Announces
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Pricing of $6.8
Material agreement · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Provides Corporate Update and Announces Third
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
Material agreement · Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Pricing of $6.5
Material agreement · Other events · EX-99.2 to Form 8-K
Quoin Pharmaceuticals Announces FDA Clearance
Other events · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Provides Corporate Update and Announces First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter And Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Quoin Pharmaceuticals Announces Pricing of $7.0
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Statements as of September 30, 2022
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Statements as of June 30, 2022
EX-99.1 to Form 6-K